Biotech firm, Energenesis Biomedical, reports favorable outcomes in Phase I trials for ENERGI-F705PD, a potential game-changer medication aiming to slow the progression of Parkinson's Disease.
In a recent press release by Cision PR Newswire, Energenesis Biomedical Co., Ltd. (TWSE: 6657) announced the planned initiation of a Phase II clinical trial for ENERGI-F705PD, an oral investigational drug for Parkinson's disease (PD). This announcement follows the successful completion of the drug's Phase I trial.
The Phase I trial, a randomized, double-blind, placebo-controlled study involving 24 healthy volunteers, demonstrated favorable safety and tolerability, validating the sustained-release oral formulation of ENERGI-F705PD. This trial marks a significant step towards developing a disease-modifying treatment for PD, rather than just symptomatic relief.
ENERGI-F705PD targets intracellular alpha-synuclein aggregation, a key pathology in PD. Mechanistically, the drug enhances the pentose phosphate pathway (PPP), increasing NADPH and thereby cellular antioxidant defense, which reduces oxidative stress implicated in PD. Additionally, ENERGI-F705PD increases expression and activity of tyrosine hydroxylase, the enzyme crucial for dopamine synthesis, helping restore neurotransmitter levels in PD patients' brains.
The upcoming Phase II trial will focus on evaluating the therapeutic efficacy of ENERGI-F705PD in patients with Parkinson's disease, moving beyond safety to clinical benefit assessment. The trial's specific design parameters, such as the number of patients, duration, and endpoints, have not been disclosed.
Energenesis Biomedical, a clinical-stage biotechnology company focused on cellular energy restoration therapeutics, has additional leading candidates beyond ENERGI-F705PD for various conditions. For instance, ENERGI-F703EB is preparing for Phase II for the treatment of Epidermolysis bullosa (EB). Moreover, ENERGI-F703DFU is in Phase III for the treatment of Diabetic foot ulcers.
Interested parties can contact the Business Development Team at [email protected] for more information. The company's website is www.energenesis-biomedical.com/en.
It is important to note that Parkinson's disease, affecting over 10 million people globally, currently has no cure, with existing treatments only managing symptoms. The development of ENERGI-F705PD offers hope for a potential disease-modifying treatment, aiming to modify Parkinson’s disease progression by targeting key biochemical and pathological mechanisms.
References: 1. Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson's Disease 2. Energenesis Biomedical Co., Ltd.
- The upcoming Phase II clinical trial, focusing on Parkinson's disease patients, aims to assess the therapeutic efficacy of ENERGI-F705PD, a potential game-changer in medical-conditions like PD, moving beyond health-and-wellness and mental-health management.
- In light of the growing number of individuals affected by PD worldwide, the progress of ENERGI-F705PD, an investigational drug targeting neurological-disorders, presents an exciting breakthrough in science and hope for those afflicted with this debilitating disorder.
- Energenesis Biomedical's research in cellular energy restoration therapeutics extends beyond Parkinson's disease, as seen in their additional leading candidates like ENERGI-F703EB for Epidermolysis bullosa and ENERGI-F703DFU for Diabetic foot ulcers, demonstrating a commitment to addressing various medical-conditions.
